Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Anesthetics in Mohs Micrographic Surgery
NCT07601750Phase 4
Key facts
- Status
- Enrolling by invitation
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Countries
- 1
- Sponsor
- Baylor Scott & White Research Institute
- Modality
- Small Molecules
- Conditions
- pain
01
Overview
Phase 4, randomised trial of bupivacaine hydrochloride 0.75% injection, mepivacaine and chloroprocaine in pain (2 arms), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Increase in pain with local injections at each stage of surgery. Started Jan 2025; status: enrolling by invitation.
02
Design
2 arms- Study design
- Randomized
Treatment Group
Patients receive bupivacaine, mepivacaine, or chlorprocaine as local anesthesia.
Standard of Care Group
Patients receive lidocaine as local anesthesia.
03
Who it enrols
Adults aged 18-89 with a cutaneous tumor undergoing Mohs Micrographic Surgery, excluding pregnant individuals.
04
Endpoints
Primary
Increase in pain with local injections at each stage of surgery
Secondary
Pain control using mepivacaine as a primary anesthetic agent
Pain control using bupivacaine with epinephrine as a primary anesthetic agent
Pain control using bupivacaine as a primary anesthetic agent
Ideal anesthetic agents for varying sizes of tumors
Ideal anesthetic agents for varying anatomic location of tumors
Overall tolerability of MMS
General length of time required for various steps of MMS
Beyond the preview
Go deeper on NCT07601750.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601750.